ECO Animal Health has appointed Dr Andrew Winder as Head of Business Development, adding new strategic leadership to its global animal health growth agenda.

The appointment was announced through ECO Animal Health’s own official LinkedIn channel. According to the company, Winder brings strategic business development experience across global animal health markets and will focus on identifying and securing new opportunities, including in-licensing partnerships, to help grow ECO’s R&D pipeline. 

ECO Animal Health is a publicly listed animal health biotech company focused on pig and poultry health. The company says it provides products for pigs and poultry to treat disease, improve health and support performance. Its lead product, Aivlosin, is described by ECO as a proprietary, patented medication used against respiratory and intestinal diseases in pigs and poultry. 

This makes the appointment more than a routine management update. In production animal health, business development increasingly shapes how companies build future portfolios, access external innovation and strengthen their position in competitive therapeutic areas. For ECO, Winder’s role connects directly to pipeline expansion and strategic partnerships, two areas that can influence long-term growth in pig and poultry health.

ECO’s own website positions the company around animal health products and solutions that support the health and welfare of pigs and poultry. The company also highlights innovation as part of its future direction, making business development an important bridge between science, market needs and commercial execution. 

Winder’s appointment comes as animal health companies continue to look for new ways to expand product pipelines through partnerships, licensing and targeted innovation. For companies serving intensive livestock markets, these decisions are closely tied to disease control, productivity and the economics of protein production.

With the new appointment, ECO Animal Health strengthens the team responsible for finding external growth opportunities and supporting the development of its future portfolio. For the pig and poultry health segments, the move signals a continued focus on innovation-led growth and strategic expansion.